Long-Term Results of the Etiotropic Therapy of Subcompensed Liver Cirrhosis in the Outcome of Chronic Hepatitis C

• Published in: Rossiĭskiĭ zhurnal gastroėnterologii, gepatologii, koloproktologii Vol. 29; no. 6; pp. 30 - 35
• Main Authors: Bogomolov, P. O., Bueverov, A. O., Bakirova, V. E., Lyusina, E. O., Fedosyina, E. A., Koblov, S. V., Sumtsova, O. V.
• Format: Journal Article
• Language: English; Russian
• Published: Gastro LLC 31.01.2020
• Subjects: chronic hepatitis c; liver cirrhosis; long-term results; treatment
• ISSN: 1382-4376; 2658-6673
• DOI: 10.22416/1382-4376-2019-29-6-30-35

Aim. The evaluation of long-term results of antiviral therapy (AVT) with ombitasvir/paritaprevir/ritonavir and dasabuvir in patients with noncompensated liver cirrhosis (LC) in the outcome of chronic hepatitis C.Material and methods. A retrospective analysis included the data from patients with subcompensated liver cirrhosis (LC) of HCV etiology (genotype 1b) (7–9 points of the Child-Pugh score) having received interferon-free antiviral therapy (AVT) with ombitasvir/paritaprevir/ritonavir and dasabuvir during 12 weeks from September to December 2015. In total, 66 patients (27 men and 39 women) received such a therapy, the median age was 56.4 years.Results. 147 weeks (IQR 56–156) following AVT completion, the long-term results were evaluated. At that time, 27 patients were available for observation. The assessment of liver function compensation using the Child-Pugh score showed improvement in 25 (93 %) patients. The assessment of laboratory data revealed a decrease in the median of total bilirubin by 13.6 μmol/l, as well as an increase in the median of serum albumin by 9.7 g/L and the median of platelets by 41,700/μl. Two deaths were reported due to hepatocellular cancer (HCC) and bleeding from esophageal varices. HCC was detected in 8 patients. Two patients underwent liver transplantation.Conclusion. AVT in patients with LC of HCV etiology is associated with a high frequency of virologic response. Longterm follow-up results indicate a significant improvement of liver function, but also a continuing high risk of developing complications of underlying disease, primarily HCC.